v2.4.0.6
Segment information
 12 Months Ended
Dec. 31, 2012
Segment Reporting [Abstract]  
Segment information
Segment information
We operate in one business segment — human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Enterprise-wide disclosures about product sales; revenues and long-lived assets by geographic area; and revenues from major customers are presented below.
Revenues
Revenues were as follows for the years ended December 31, 2012, 2011 and 2010 (in millions):
 
2012
 
2011
 
2010
Product sales:
 
 
 
 
 
Neulasta® 
$
4,092

 
$
3,952

 
$
3,558

NEUPOGEN® 
1,260

 
1,260

 
1,286

ENBREL
4,236

 
3,701

 
3,534

Aranesp® 
2,040

 
2,303

 
2,486

EPOGEN® 
1,941

 
2,040

 
2,524

Sensipar®/Mimpara®
950

 
808

 
714

Vectibix® 
359

 
322

 
288

Nplate® 
368

 
297

 
229

XGEVA® 
748

 
351

 
8

Prolia® 
472

 
203

 
33

Other
173

 
58

 
—

Total product sales
16,639

 
15,295

 
14,660

Other revenues
626

 
287

 
393

Total revenues
$
17,265

 
$
15,582

 
$
15,053


Geographic information
Outside the United States, we sell products principally in Europe and Canada. The geographic classification of product sales was based on the location of the customer. The geographic classification of all other revenues was based on the domicile of the entity from which the revenues were earned.
Certain geographic information with respect to revenues and long-lived assets (consisting of property, plant and equipment) was as follows (in millions):
 
Years ended December 31,
 
2012
 
2011
 
2010
Revenues:
 
 
 
 
 
United States
$
13,415

 
$
11,985

 
$
11,636

ROW
3,850

 
3,597

 
3,417

Total revenues
$
17,265

 
$
15,582

 
$
15,053

 
December 31,
 
2012
 
2011
Long-lived assets:
 
 
 
United States
$
2,906

 
$
3,144

Puerto Rico
1,908

 
1,993

ROW
512

 
283

Total long-lived assets
$
5,326

 
$
5,420


Major customers
In the United States, we sell primarily to pharmaceutical wholesale distributors. We utilize those wholesale distributors as the principal means of distributing our products to healthcare providers. In Europe, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers, and we limit our credit exposure by setting credit limits and, for certain customers, by requiring letters of credit.
We had product sales to three customers each accounting for more than 10% of total revenues for the years ended December 31, 2012, 2011 and 2010. For 2012, on a combined basis, these customers accounted for 76% and 94% of worldwide gross revenues and U.S. gross product sales, respectively, as noted in the following table. Certain information with respect to these customers for the years ended December 31, 2012, 2011 and 2010, was as follows (dollar amounts in millions):
 
2012
 
2011
 
2010
AmerisourceBergen Corporation:
 
 
 
 
 
Gross product sales
$
7,556

 
$
7,574

 
$
7,678

% of total gross revenues
34
%
 
36
%
 
38
%
% of U.S. gross product sales
43
%
 
45
%
 
47
%
McKesson Corporation:
 
 
 
 
 
Gross product sales
$
5,898

 
$
4,591

 
$
3,913

% of total gross revenues
27
%
 
22
%
 
19
%
% of U.S. gross product sales
32
%
 
27
%
 
24
%
Cardinal Health, Inc.:
 
 
 
 
 
Gross product sales
$
3,245

 
$
3,021

 
$
2,813

% of total gross revenues
15
%
 
14
%
 
14
%
% of U.S. gross product sales
19
%
 
18
%
 
17
%

At December 31, 2012 and 2011, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 61% and 60%, respectively, of net trade receivables on a combined basis. At December 31, 2012 and 2011, 36% and 39%, respectively, of trade receivables, net were due from customers located outside the United States, primarily in Europe. Our total allowance for doubtful accounts as of December 31, 2012 and 2011, was not material.